This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients (PIGREC)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Limoges Identifier:
First received: December 19, 2008
Last updated: August 23, 2013
Last verified: December 2008

The main objective is to develop pharmacokinetic methods for individual dose adjustment of the global immunosuppressive treatment (cyclosporine, tacrolimus, mycophenolate mofetil and everolimus, taking into account the pharmacokinetic interactions), in order to optimise the efficiency and reduce the potentially severe sides effects of these drugs.

Forty five heart-transplant patients are to be included in this phase IV study to obtain a minimum of 10 patients treated with tacrolimus-mycophenolate, 10 with cyclosporine-mycophenolate and 20 with everolimus-cyclosporine.

Ten to 11 blood samples will be collected within the 8 to 12 hours post-dose in each patient and the immunosuppressive drug concentrations will be measured by LC-MS/MS.

The pharmacokinetic models and Bayesian estimators thus developed will provide tools for individual dose adjustment of immunosuppressive drugs simultaneously, at different post-transplant periods, using the area under the concentration-time curve (AUC) estimated using a limited number of time-points (2 or 3).

Condition Intervention Phase
Heart Transplant Drug: cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-grafting in Adult Heart Transplant Recipients.

Resource links provided by NLM:

Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • Estimation of the pharmacokinetic properties and parameters of the immunosuppressive drugs.

Secondary Outcome Measures:
  • Investigation of relationships between physiological and pathological characteristics and individual pharmacokinetic parameters.
  • Characterisation of the exposure-clinical effects relationships for the difference immunosuppressive drugs.

Enrollment: 42
Study Start Date: July 2007
Study Completion Date: May 2012
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:
For each heart transplant patient, 10 to 11 blood samples (5 mL each) will be collected following dosing of he immunosuppressive drugs (at T0, T20', T40', T60', T90', T2h, T3h, T4h, T6h, T8h and T10h + T12h for inpatients), at several post-transplant periods (7 to 15 days, 1 month, 3 month and 1 year after transplantation). One more blood sample will be taken at D7-14 for pharmacogenetic analyses.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient having received of a heart transplant (exclusively) less than 2 weeks before the inclusion date or planned to receive it within days following inclusion.
  • Patient at least 18 years old, male or female.
  • Patient treated with one of the following combination : cyclosporine-mycophenolate, tacrolimus-mycophenolate or everolimus- "low-dose" cyclosporine for at least 3 days, and at least 24 hours by the oral route at the time of the first sampling day (between 7 and 15 days post-transplant).
  • Patient included or not in another study, in particular in a therapeutic trial (e.g. comparison between drug combinations).
  • Patient having given written informed consent for his/her participation to the trial.

Exclusion Criteria:

  • Patients in disagreement with the present trial.
  • Patients suffering from neuro-psychic problems, making them unable to well-understand the protocol or to give a reliable consent.
  • Patients with previous heart or any other solid organ transplantation.
  • Patients with double transplantation (heart-lung, heart-kidney or heart-liver)
  • Patients still intubated and ventilated 15 days post-transplant.
  • Patients with anaemia between Day 7 and 15, as characterized by hematocrit < 30% or haemoglobin < 9 g/dl.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00812786

CHU de Bordeaux
Bordeaux, France
CHU de Clermont-Ferrand
Clermont-ferrand, France
CHU de Lille
Lille, France
CHU de Limoges
Limoges, France
Hôpital Louis Pradel - CHU de Lyon
Lyon, France
CHU de Nantes
Nantes, France
Hôpital Européen Georges Pompidou
Paris, France
Hôpital Pitié-Salpêtrière
Paris, France
CHU de Rennes
Rennes, France
CHU de Rouen
Rouen, France
CHU de Strasbourg
Strasbourg, France
Vandoeuvre Les Nancy, France
Sponsors and Collaborators
University Hospital, Limoges
Principal Investigator: Pierre MARQUET, MD University Hospital, Limoges
  More Information

Responsible Party: University Hospital, Limoges Identifier: NCT00812786     History of Changes
Other Study ID Numbers: 2006-006832-23
Study First Received: December 19, 2008
Last Updated: August 23, 2013

Keywords provided by University Hospital, Limoges:
heart transplantation
immunosuppressive drugs
individual dose adjustment

Additional relevant MeSH terms:
Mycophenolic Acid
Mycophenolate mofetil
Immunosuppressive Agents
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Antirheumatic Agents processed this record on September 19, 2017